The likelihood of having a serum PSA level of >= 2.5 ng/mL according to the degree of fatty liver disease in a screened population
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Jong Hyun | - |
dc.contributor.author | Yang, Hee Jo | - |
dc.contributor.author | Kim, Jae Heon | - |
dc.contributor.author | Doo, Seung Whan | - |
dc.contributor.author | Yang, Won Jae | - |
dc.contributor.author | Hwang, Jiyoung | - |
dc.contributor.author | Hong, Seong Sook | - |
dc.contributor.author | Park, Suyeon | - |
dc.contributor.author | Cho, Dae Yeon | - |
dc.date.accessioned | 2021-08-11T19:25:43Z | - |
dc.date.available | 2021-08-11T19:25:43Z | - |
dc.date.issued | 2015-11 | - |
dc.identifier.issn | 1911-6470 | - |
dc.identifier.issn | 1920-1214 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/10156 | - |
dc.description.abstract | Introduction: We sought to investigate the impact of fatty liver disease (FLD) on prostate cancer (PCa) screening by estimating the odds of having a prostate-specific antigen (PSA) value over the cutoff used to prompt for the recommendation of prostate biopsy. Methods: Between 2007 and 2013, 18 533 native Korean men eligible to receive a serum PSA test, liver profiles, and abdominal ultrasonography were recruited. Logistic regression was used to estimate the odds of an abnormal PSA (>= 2.5 ng/mL) in these men (age 45-75 years, PSA <= 10 ng/mL) in relation to FLD. The FLD status was categorized as normal, mild, moderate, and severe grade by abdominal sonography. Results: A total of 16 563 men (89.4%) were included in the study after applying the inclusion criteria. Liver profiles were negatively correlated with the serum PSA level. After controlling for age and obesity, there was a statistically significant trend towards a lower likelihood of having a serum PSA level of >= 2.5 ng/mL with severe FLD, having a 34.7% lower likelihood (odds ratio 0.653, 95% confidence interval 0.477-0.88; p<0.01) compared to men in the normal group. Conclusions: Severe FLD is an independent predictor of a lower likelihood of having abnormal PSA level. Further studies are needed to better define these results in clinical biopsy practice. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Canadian Urological Association | - |
dc.title | The likelihood of having a serum PSA level of >= 2.5 ng/mL according to the degree of fatty liver disease in a screened population | - |
dc.type | Article | - |
dc.publisher.location | 캐나다 | - |
dc.identifier.doi | 10.5489/cuaj.2395 | - |
dc.identifier.scopusid | 2-s2.0-84949672758 | - |
dc.identifier.wosid | 000373177500023 | - |
dc.identifier.bibliographicCitation | Journal of the Canadian Urological Association, v.9, no.11-12, pp E868 - E872 | - |
dc.citation.title | Journal of the Canadian Urological Association | - |
dc.citation.volume | 9 | - |
dc.citation.number | 11-12 | - |
dc.citation.startPage | E868 | - |
dc.citation.endPage | E872 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | PROSTATE-SPECIFIC ANTIGEN | - |
dc.subject.keywordPlus | HEPATIC CIRRHOSIS | - |
dc.subject.keywordPlus | OBESITY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | MEN | - |
dc.subject.keywordPlus | TESTOSTERONE | - |
dc.subject.keywordPlus | RATES | - |
dc.subject.keywordAuthor | The likelihood of having a serum PSA level of ≥2.5 ng/mL accordingto the degree of fatty liver disease in a screened population | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.